3.4 Million
Dialaysis patient worldwide
[1,3]

Diabetes and high blood pressure are the most prevalent causes of kidney disease. Patients with end stage kidney disease require their blood to be routinely filtered externally through haemodialysis.

Globally, the number of patients with kidney failure grows by 6% annually, resulting in an estimated 4.9 million patients in 2025.

Vascular Access Creation

For the last 50 years, open surgery has been the current gold standard for preparing patients for dialysis. This involves suturing together an artery and vein in the forearm to create a vascular access site (Arteriovenous Fistula or AVF) for the dialysis machine to connect to.

640,000

surgical AVF creations per year
[2,3]

Surgical AVF Outcomes

High failure rates of surgical AVFs means they require repeat procedures to be salvaged as they are a patient’s lifeline and crucial to receiving life saving dialysis treatment.

25%
Surgical
Failure
50%
1 year
patient

3.43

Salvage Procedures
Per patient year
[19]

3-6

Months
Time to heal and mature

Cost of Failure

$5,000 to
$15,000
per salvage procedure
$4.6
Billion
US yearly spend on failing
dialysis access sites

The ePATH endoAVF system aims to reduce the burden on patients and healthcare systems through  a more reliable alternative to surgical AVF creation.

Peripheral Arterial Disease

Diabetes is also a major cause for peripheral arterial disease.

A Chronic Total Occlusion (CTO) is the most severe stage of the disease and presents a serious risk of amputation due to the complete lack of blood flow.

194,000

amputations p.a. in the US and UK

22-30
Million

with most advanced
stage (CTO)

60%

Average
Re-entry
Success Rate

The ePATH Re-Entry catheter kit will provide clinicians with a safer, more precise, and more reliable approach to CTO True Lumen Re-entry procedures.

110,000

Peripheral CTO procedures globally p.a. (2020)
[20]